First NDIN-Completed Akkermansia muciniphila for Muscle Health: BiomeNrich™ POST M005
Akkermansia muciniphila: A Microbe with Global Recognition
Akkermansia muciniphila is well-known for its role in gut and metabolic health, with research highlighting its benefits for weight management, inflammation reduction, and metabolic disease prevention. Until now, regulatory hurdles have limited its commercial use. The FDA's acknowledgment of BiomeNrich™ POST M005 through the NDIN process ensures its safety for dietary applications, paving the way for broader industry adoption.
BiomeNrich™ POST M005: A Stable and Effective Postbiotic
BiomeNrich™ POST M005 is a postbiotic- comprised of inactivated microbes through a pasteurization process- offering enhanced stability, safety and efficacy over traditional probiotics.
A randomized, double-blind, placebo-controlled clinical trial with 92 participants over 12 weeks assessed its efficacy in supporting muscle health. The study measured improvements in muscle strength and function, showing:
- 200% increase in leg strength vs. placebo
- 130% increase in follistatin, a key muscle-supporting protein
The full study is available here: Read more
Access the white paper: Download here
About CJ BIO Taste & Nutrition Business
View original content to download multimedia:https://www.prnewswire.com/news-releases/first-ndin-completed-akkermansia-muciniphila-for-muscle-health-biomenrich-post-m005-302413038.html
SOURCE
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Insilico Medicine Included in the HKEX Tech 100 Index, Drawing Attention to Opportunities in AI Value Chain
- Dr. Donna Pontoriero Launches Dr. Donna Institute, Bringing 30+ Years of Real-World Health and Wellness Experience to a New Education Platform
- The Royal Mint Boldly Goes Where No Coin Has Gone Before With New Star Trek 50p Coins
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share